Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10093713 GIP-GLP-1 dual agonist compounds and methods

Patent 10093713 was granted and assigned to Zealand Pharma A/S on October, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Zealand Pharma A/S

Current Assignee

Zealand Pharma A/S

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

100937130

Patent Inventor Names

Anne Pernille Tofteng Shelton0

Jacob Ulrik Fog0

Pia Nørregaard0

Carsten Boye Knudsen0

Date of Patent

October 9, 2018

Patent Application Number

150347780

Date Filed

November 6, 2014

Patent Citations Received

‌

US Patent 11884713 Acylated glucagon analogues

‌

US Patent 10253078 GIP agonist compounds and methods

‌

US Patent 10336802 Acylated glucagon analogue

‌

US Patent 10457714 Acylated glucagon analogues

‌

US Patent 11001619 GIP agonist compounds and methods

‌

US Patent 11008375 GIP-GLP-1 dual agonist compounds and methods

‌

US Patent 11034747 Glucagon analogues and methods of use

‌

US Patent 11274136 Acylated glucagon analogue

Patent Primary Examiner

‌

Marcela M Cordero Garcia

Patent abstract

The present invention relates to acylated GIP analogs which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10093713 GIP-GLP-1 dual agonist compounds and methods

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API